Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026)
Macrogenics' (MGNX) quarterly Total Non-Current Liabilities came in at $195.9 million in Q1 2026, up 36.57% year-on-year from $143.5 million in Q1 2025, and down 2.13% on a QoQ basis from $200.2 million in Q4 2025.
Macrogenics (MGNX) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 12 years of Total Non-Current Liabilities data on file, last reported at $195.9 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 36.57% year-over-year to $195.9 million in Q1 2026; TTM through Mar 2026 was $195.9 million, a 36.57% increase from a year earlier, with the FY2025 full-year figure at $200.2 million, up 39.39% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $195.9 million, down from $200.2 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for MGNX reached as high as $234.0 million in Q1 2023 and fell as low as $72.1 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $150.0 million across 5 years, with a median of $143.6 million in 2024.
- Across the five-year window, Total Non-Current Liabilities surged 151.66% in 2023 and plunged 39.36% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $138.2 million in 2022, then increased by 5.32% to $145.5 million in 2023, then fell by 1.32% to $143.6 million in 2024, then soared by 39.39% to $200.2 million in 2025, then dropped by 2.13% to $195.9 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $195.9 million in Q1 2026, $200.2 million in Q4 2025, and $202.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Macrogenics | 254.43 Mn | 187.92 Mn | - | 195.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 195.95 Mn |
| Dec 31, 2025 | 200.20 Mn |
| Sep 30, 2025 | 202.43 Mn |
| Jun 30, 2025 | 197.13 Mn |
| Mar 31, 2025 | 143.48 Mn |
| Dec 31, 2024 | 143.63 Mn |
| Sep 30, 2024 | 144.17 Mn |
| Jun 30, 2024 | 143.06 Mn |
| Mar 31, 2024 | 141.87 Mn |
| Dec 31, 2023 | 145.55 Mn |
| Sep 30, 2023 | 145.73 Mn |
| Jun 30, 2023 | 133.85 Mn |
| Mar 31, 2023 | 233.97 Mn |
| Dec 31, 2022 | 138.20 Mn |
| Sep 30, 2022 | 72.13 Mn |
| Jun 30, 2022 | 75.30 Mn |
| Mar 31, 2022 | 92.97 Mn |
| Dec 31, 2021 | 95.37 Mn |
| Sep 30, 2021 | 100.46 Mn |
| Jun 30, 2021 | 106.61 Mn |